The binding epitope of Lcn2 antibody was mapped to its β3 and β4 strands, which are responsible for maintaining the integrity of the Lcn2 cup-shaped structure [72], indicating that Lcn2 can be pharmacologically targeted using a specific antibody to reduce reperfusion injury after ischemia and suggesting that early detection and inhibition of Lcn2 may prove useful in the diagnosis and treatment of post-ischemia memory impairment. The gene discussed is LCN2; the disease is memory impairment.